CHARLOTTESVILLE, Va., June 20, 2014 /PRNewswire/ -- HemoShear, LLC, the human disease biology company, today announced that CBO Vince Aurentz will be presenting at the BIO 2014 meeting during the BIO Business Forum on Tuesday, June 24 at 11:00 a.m. in the Solana Beach Room. Aurentz's presentation, "Recreating Human Disease Biology for Discovery and Development of Safer and More Effective New Drugs", will focus on HemoShear's business strategy and how the Company is collaborating with its pharmaceutical R&D partners.

HemoShear is also part of the select group of organizations participating in the NIH Innovation Zone at the Biotechnology Industry Organization's 2014 annual convention. Hosted by the National Science Foundation (NSF) and the National Institutes of Health (NIH), this newly created Innovation Zone will showcase notable recipients of Small Business Innovation Research (SBIR) grants, which provide U.S. federal funding to small businesses engaged in research with the potential for commercialization. Brian Wamhoff, PhD, Co-Founder and Vice President of R&D of HemoShear, will give a presentation on applications of the Company's platform on Wednesday, June 25 at 3:00 p.m. at the NIH booth #4707, Hall A, in the Discovery Zone.

HemoShear has received more than $8 million in SBIR funding across four different NIH institutes, a testament to the broad scientific support of HemoShear's platform and its potential to discover new drugs across a wide range of therapeutic areas. The Company recently received the prestigious SBA Tibbetts Award for SBIR excellence. HemoShear is developing and applying human disease systems that provide a better way to predict how patients will react and respond to a drug candidate, improving its probability of success, resulting in safer, more effective therapies for patients, and potentially lowering drug development costs for the pharmaceutical industry.

HemoShear is available for meetings and interviews at booth #5449, located within the NIH Innovation Zone.

About HemoShear, the Human Disease Biology CompanyHemoShear is a biotechnology company that is changing the way drugs are discovered and developed in a broad range of therapeutic areas, departing from traditional scientific methods and animal studies in favor of translational tissue systems that more accurately replicate human response. We work in strategic collaboration with pharmaceutical and biotechnology companies spanning discovery through clinical applications to uncover new targets, elucidate previously unknown mechanisms, identify novel attributes of drugs and select candidates with superior efficacy and safety profiles. Our proprietary platform integrates patented first-in-class human disease systems with advanced discovery and predictive BioAnalytics and interdisciplinary scientific expertise, providing a unique and powerful lens to interpret biological mechanisms and human disease. Through our pioneering science, HemoShear's mission is to profoundly impact human health. THINK HUMAN.